Cargando…
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database()
BACKGROUND: Despite the best standard treatment, optimal cytoreductive surgery (CRS) and platinum/taxane-based chemotherapy, prognosis of advanced epithelial ovarian carcinoma (EOC) remains poor. Recently, CRS plus hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed to treat periton...
Autores principales: | Sun, Jian-Hua, Ji, Zhong-He, Yu, Yang, Wu, Hai-Tao, Huang, Chao-Qun, Zhang, Qian, Yang, Xiao-Jun, Yonemura, Yutaka, Li, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833965/ https://www.ncbi.nlm.nih.gov/pubmed/27084429 http://dx.doi.org/10.1016/j.tranon.2016.02.002 |
Ejemplares similares
-
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study
por: Tang, Li, et al.
Publicado: (2011) -
Long term survival of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in advanced epithelial ovarian cancer
por: Zhang, Jue, et al.
Publicado: (2021) -
Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan
por: Hsieh, Mao-Chih, et al.
Publicado: (2017) -
Experience of applying cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian teratoma with malignant transformation and peritoneal dissemination
por: Yu, Hsin-Hsien, et al.
Publicado: (2019) -
Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer
por: Chen, Wei-Chun, et al.
Publicado: (2022)